Editas Medicine Inc. (EDIT)
Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) 7th Annual Evercore HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Erick Lucera - Executive Vice President and Chief Financial Officer Cristi Barnett - Senior Vice President, Corporate Communications and Investor Relations Conference Call Participants Liisa Bayko - Evercore ISI Liisa Bayko Okay, welcome everyone. This is Evercore's Healthcare Conference.
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
BofA Securities downgraded Editas Medicine Inc EDIT, citing few value-driving catalysts in the near term.
Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) Stifel 2024 Healthcare Conference November 19, 2024 1:50 PM ET Company Participants Erick Lucera - Chief Financial Officer Conference Call Participants Dae Gon Ha - Stifel Dae Gon Ha All right. Thanks, everyone, for joining us for the next half hour.
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y
EDIT reports mixed third-quarter 2024 results as earnings beat expectations while revenues miss the same.
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.55 per share a year ago.
Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down
Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies
Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.
Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript
Editas Medicine, Inc. (NASDAQ:EDIT ) Strategic Update Conference Call October 22, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - Chief Executive Officer Linda Burkly - Chief Scientific Officer Erick Lucera - Chief Financial Officer Baisong Mei - Chief Medical Officer Caren Deardorf - Chief Commercial and Strategy Officer Conference Call Participants Samantha Semenkow - Citi Gena Wang - Barclays Jack Allen - Baird Yanan Zhu - Wells Fargo Soumit Roy - Jones Brian Cheng - JPMorgan Chase Joon Lee - Truist Dae Gon Ha - Stifel Alec Stranahan - Bank of America Rick Bienkowski - Cantor Phil Nadeau - TD Cowen Liisa Bayko - Evercore Mani Foroohar - Leerink Partners Timur Ivannikov - Raymond James Operator Good morning, everyone, and thank you for joining Editas Medicine's Strategic Update Webinar. This webinar is being recorded and can be accessed in the future through this same link or through the Investor section of the company's website.
Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations
Shares of Editas Medicine, Inc. (EDIT, Financial), a biopharmaceutical company, experienced a notable drop of 5.18%. The stock is currently priced at $3.21 per share, with a trading volume of 976,255 shares and a turnover rate of 1.18%.
Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) Chardan's 8th Annual Genetic Medicines Conference October 1, 2024 3:45 PM ET Company Participants Erick Lucera - CFO Cristi Barnett - VP Corporate Communications and IR Conference Call Participants Geulah Livshits - Chardan Geulah Livshits I'm Geulah Livshits, a biotech analyst at Chardan and it's my pleasure to introduce Erick Lucera, our CFO; and Cristi Barnett, VP Corporate Communications and IR at Editas. Thank you both for joining us today.
Editas Medicine: A Risk/Reward Worth Considering
Editas Medicine has made significant progress in advancing reni-cel, their in-vivo editing pipeline, and business development, despite a 65% drop in stock price. Reni-cel shows promising clinical results for sickle cell disease and beta-thalassemia, with potential BLA submission by year-end, enhancing its risk-reward profile. Editas' in-vivo pipeline and strategic partnerships bolster its position, but competition and regulatory challenges remain significant risks.
